Artan

Quick links to important sections

Artan

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Artan

Property Description
Active ingredient Trihexyphenidyl Hydrochloride (Trihexyphenidyl HCl)
Form Tablet, Elixir (oral solution)
Pharmacological class Anticholinergic agent, Antiparkinson agent
Common use Improve muscle control, reduce tremors
Origin Synthetic chemical compound

Trihexyphenidyl (Artan): Definition and Pharmacological Class

Artan is a synthetic, prescription-only medication whose active ingredient is Trihexyphenidyl Hydrochloride (Trihexyphenidyl HCl), also recognized by the generic name Benzhexol. This single-ingredient substance is primarily classified as a centrally acting Anticholinergic agent.

The principal pharmacological class is Antiparkinson agent. Trihexyphenidyl possesses antiparkinson activity. Unlike some therapies that modulate dopamine, Artan’s unique feature is its ability to directly block acetylcholine activity, providing an alternative mechanism for managing motor imbalances.

Composition and Available Forms of Artan

The active ingredient, Trihexyphenidyl HCl, is the sole therapeutic component, supplied for the Oral route in two distinct pharmaceutical preparations: a solid Tablet and a liquid Elixir (oral solution).

The availability of both the Tablet and the Elixir dosage forms is a key feature, allowing for flexible administration tailored to individuals who may have swallowing difficulties or require adjustments to the concentration of active ingredient. The Elixir form uses a liquid vehicle, contrasting with the excipients found in the solid tablet preparation.

General Purpose: Why Artan is Used

Artan is principally utilized as an Antidyskinetic Agent to improve muscle control in disorders involving involuntary or impaired movement. Its general therapeutic purpose is to help relieve symptoms such as tremors and stiffness.

This application relates to the drug’s ability to dampen excessive signaling in the motor pathways. Artan’s role as an adjunct therapy is to support the management of motor coordination by influencing the central nervous system.

Regulatory References

  1. Trihexyphenidyl on WHO Electronic Essential Medicines List (eEML)

What side effects are possible with Artan?

Possible Side Effects and Safety Information

The safety profile of Artan (Trihexyphenidyl) is officially documented by regulatory authorities, detailing potential adverse reactions and specific safety patterns, primarily reflecting its anticholinergic activity.

Frequency and System-Organ Effects

Adverse reactions are classified by the affected physiological system. A group of Minor Side Effects is reported to affect approximately 30 to 50 percent of all patients, including dryness of the mouth, blurred vision, dizziness, mild nausea, and nervousness [NIH DailyMed]. Regulatory text notes that these common effects often become less pronounced as treatment continues.

Observed effects are grouped by system, including Ocular (e.g., blurred vision, dilation of the pupil), Gastrointestinal (e.g., constipation, paralytic ileus), Nervous System/Psychiatric (e.g., drowsiness, confusion, agitation), and Renal and Urinary (e.g., urinary hesitancy or retention).


Serious Adverse Reactions and Safety Constraints

Regulatory documentation highlights potentially serious adverse reactions. These include the risk of Angle-Closure Glaucoma (reported with long-term use) and Neuroleptic Malignant Syndrome (NMS), which has been associated with abrupt cessation of the medicine [FDA Accessdata]. Isolated instances of Fatal Hyperthermia and Severe Anhidrosis (heat stroke risk) are also noted, particularly when the drug is used in hot weather.

The drug is contraindicated in patients with known narrow-angle glaucoma or hypersensitivity to its components. Due to the potential for increased sensitivity, Geriatric Patients (over age 60) may frequently develop reactions such as mental confusion or disturbed behavior and require close observation [NIH DailyMed].

Overdose and Emergency Response

The official regulatory profile for an Artan (Trihexyphenidyl) overdose is defined by severe anticholinergic manifestations that can rapidly lead to life-threatening systemic outcomes. Documented clinical manifestations include peripheral effects such as dry mouth, flushed skin, dilated pupils (mydriasis), increased intraocular tension, and urinary retention. These are often accompanied by serious Central Nervous System (CNS) disturbances, including restlessness, confusion, delirium, hallucinations, psychotic reactions, and convulsions.

When to Seek Immediate Medical Help

Immediate medical attention is mandated for any suspected overdose. Emergency services must be contacted if the individual exhibits severe signs such as collapse, seizure, trouble breathing, or inability to be awakened. These symptoms indicate the potential for escalation to critical outcomes listed in regulatory documents, including circulatory failure, respiratory failure, or coma.

Official Management and Treatment

Regulatory documents confirm that management is always supportive and symptomatic. Procedures include establishing and maintaining an adequate airway and correcting physiological imbalances such as hypoxia and acidosis. While no specific antidote is detailed in the labeling, regulatory guidance explicitly states that antiarrhythmic drugs are not recommended if cardiac dysrhythmias occur. Close hospital monitoring of vital signs and intraocular pressures may be required.

Therapeutic Uses of Artan

The therapeutic use of Artan (Trihexyphenidyl) is centered on supportive symptom management in conditions that affect muscle control. Artan is commonly used to help with multiple symptom domains related to movement disorders.

Artan is relevant for conditions characterized by periods of heightened symptoms associated with Parkinsonism (including idiopathic forms) and Extrapyramidal Symptoms caused by other central nervous system drugs. It plays a role in managing symptom clusters that may become intense, such as tremor, rigidity, slowness of movement, severe muscle reactions, and excessive salivation. This application is relevant when supportive symptom management is appropriate to address movement disturbances.

Quick Fact: Addressing Rigidity and Tremor Applied in addressing the physical manifestations of muscle stiffness and involuntary shaking, which supports general well-being during symptomatic phases.

“Artan is applied across domains where additional symptomatic support is needed to address movement disturbances caused by certain other central nervous system drugs.”

Its use is associated with supporting patients during episodes of heightened discomfort, assisting with maintaining functional stability. Its application is intended to support relief when symptoms interfere with routine activities, which may help patients cope with symptom fluctuations.

Eligibility and Restrictions for Use

Artan (Trihexyphenidyl) Eligibility and Restrictions

Official regulatory documents define strict population eligibility for Artan, which is primarily intended for Adults with Parkinsonism or drug-induced Extrapyramidal Disorders. Eligibility is determined by age, underlying medical conditions, and physiological status.

Absolute Prohibitions (Contraindications)

Category Restriction Detail
Narrow Angle Glaucoma The medicine is strictly contraindicated.
Hypersensitivity Individuals with a known allergy to Trihexyphenidyl HCl or any formulation ingredients must not use Artan.

Restricted and Conditional Use

Population Group Regulatory Status
Pediatric Population Use is not recommended; safety and effectiveness have not been established.
Pregnancy / Lactation Should not be used during breastfeeding and only if clearly necessary during pregnancy.
Geriatric Patients Require strict dosage regulation due to increased sensitivity.
Organ/Tract Disorders Use with caution in patients with Glaucoma (other forms), Obstructive Disease of the GI/GU Tracts, and Cardiac/Renal/Liver disorders (requires close monitoring).

Artan is also not recommended for patients with only Tardive Dyskinesia unless concurrent Parkinson's disease is present.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define the interaction profile of Artan (Trihexyphenidyl) primarily through two high-level mechanisms: pharmacodynamic reinforcement and exposure modification of co-administered drugs. The most significant concern involves the potential for additive effects due to its classification as an anticholinergic agent.

Documented Drug-Drug Interactions

Co-administration with other Parasympathetic Inhibitors, Tricyclic Antidepressants (TCAs), and Monoamine Oxidase Inhibitors (MAOIs) may result in intensified anticholinergic effects (e.g., dry mouth, blurred vision). Agents classified as CNS Depressants (including Opiates and Barbiturates) may have additive sedative effects when taken with Artan. Furthermore, Trihexyphenidyl may be antagonistic to the actions of gastrointestinal motility agents like Metoclopramide and Domperidone.

Exposure and Timing Constraints

The absorption of co-administered Levodopa may be reduced, an officially documented exposure modification. Labeling indicates that the dose of each agent may need reduction when used together. No specific time-separation rules are formally mandated in the primary prescribing information. The regulatory labeling contains a contraindication for use in individuals with narrow-angle glaucoma.

Substance and Population Notes

Official documents caution that the use of alcohol or Cannabinoids may cause increased sedative effects. Specific population notes exist for geriatric patients, for whom the co-administration with other anticholinergics poses a heightened danger of precipitating conditions like urinary retention or acute glaucoma.

Mechanism of Action

Central Antagonism of Cholinergic Signals

Artan's mechanism of action is defined by its ability to alter signaling in the brain's motor pathways via neurotransmitter interference. The active molecule, Trihexyphenidyl, functions as a competitive antagonist primarily targeting the muscarinic acetylcholine receptors ( mAChRs) within the central nervous system (CNS). This binding prevents the naturally occurring neurotransmitter acetylcholine from activating these receptors, thereby reducing excitatory signaling in the striatum—a key regulatory center for movement. This molecular action is the starting point of the mechanistic cascade.

Altering Striatal Neurotransmitter Balance

The mechanism contributes to an altered balance between the excitatory cholinergic system and the opposing inhibitory dopaminergic system in the nigrostriatal pathway. By reducing the influence of acetylcholine, the mechanism functionally shifts the neurochemical equilibrium, favoring the dopaminergic system's influence . This pathway adjustment affects the regulation of motor responses, leading to the physiological reduction of hyperkinetic signaling.

Dosage and Administration Information

How Artan (Trihexyphenidyl) is Used

Artan is administered solely via the oral route, utilizing the available Tablet (e.g., 2 mg, 5 mg) or Elixir (oral solution, e.g., 2 mg/5 mL) dosage forms.


Dosing Initiation and Adjustment

Therapy with Artan follows a structured, gradual titration protocol. Treatment typically begins with a low daily dose, often 1 mg per day for Parkinsonism. The total daily dose is subsequently increased in 2 mg increments at intervals of three to five days to determine a level for symptomatic management.

Standard Dosing: The common maintenance total daily dose usually ranges from 6 mg to 10 mg. The established maximum daily amount for some indications, such as drug-induced parkinsonism, may extend up to 15 mg.


Administration Schedule and Context

The total daily dose is generally split into multiple divided doses to be taken throughout the day for better tolerance, frequently divided into three doses aligned with mealtimes. Total daily amounts exceeding 10 mg are often divided into four parts.

The medication may be taken before or after meals. Timing flexibility is employed to manage common responses; for instance, administration before meals may be preferred if the medicine causes excessive dry mouth, while taking it after meals may be useful if it causes nausea. Thirst can be managed with gum or water.


Usage Patterns

Artan is generally intended for long-term use and should not be stopped abruptly, as rapid withdrawal may cause symptoms to return severely. For older adults (over 60 years), it is standard to start with a low initial dose and increase it very gradually.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Artan (Trihexyphenidyl)


Artan Studies for Parkinsonism and Motor Symptoms

The evidence base for Artan's use in conditions involving Parkinsonism—including idiopathic, post-encephalitic, and arteriosclerotic forms—is derived from a mix of short-term Randomized Controlled Trials (RCTs) and older comparative trials. Research explored how symptoms changed over time in adult populations, often including those already receiving other antiparkinson agents.

Studies monitored outcomes related to physical discomfort, specifically by measuring the impact on signs like tremor and rigidity using standardized motor scales. Findings describe patterns observed in these studies where the research highlights measured changes in the tremor sub-score during the study period. Reported data on comparative efficacy show patterns related to how motor function change differed between Artan and dopaminergic therapies.


Research on Drug-Induced Movement Disorders

Artan was studied for the control of Extrapyramidal Symptoms (EPS), which are movement disturbances caused by certain central nervous system medications, such as antipsychotics. The research base here includes a long history of observational cohort studies and clinical reviews.

These studies focused on outcomes describing episodic or acute changes, specifically monitoring changes in symptoms related to the stabilization of conditions like acute rigidity and dystonia. The evidence contributes to the broader evidence landscape related to addressing acute episodes where symptoms become more noticeable. Its role was observed in clinical settings for the control of established drug-induced EPS.


Key Uncertainties and Research Gaps

While Artan was observed in clinical use over many decades, long-term effects are not fully established by modern, prospective, controlled trials. The evidence base relies on a mix of foundational studies from different eras, meaning that the evidence quality varies across studies.

Specifically, research has also explored the potential use of Artan in children with secondary dystonia, but the systematic evidence suggests that findings were mixed across these small-scale RCTs. Consequently, the evidence is limited and heterogeneous for this specific population, and certainty remains low regarding a consistent effect. Data for certain groups remain insufficient to draw strong, individualized conclusions, highlighting what is known—and what is still uncertain.

Frequently Asked Questions (FAQ)

Common questions about Artan (FAQ)


Q: Is Artan in the same class of medicines as [A similar drug name]?

According to the official product information, the active ingredient in Artan is classified as a centrally acting anticholinergic agent and an antiparkinson agent. These classifications describe the therapeutic category and its primary function of blocking specific nerve signals in the brain.


Q: Are the side effects of Artan long-term?

Official documentation describes common, minor side effects like dry mouth or dizziness often becoming less pronounced as treatment continues. However, the documentation does not provide specific details on the long-term persistence or duration of all possible reactions.


Q: Can Artan affect my ability to drive or operate machinery?

Regulatory labeling states that the medicine may impair mental and/or physical abilities required for performing hazardous tasks. This includes operating machinery or driving a motor vehicle.


Q: What is the risk of dependence or addiction with Artan?

Official product information contains sections cautioning against indiscriminate use to sustain feelings of euphoria and discusses the potential for psychiatric disturbances. Regulatory text focuses on these risks related to inappropriate use.


Q: Can Artan interact with high blood pressure medicines?

Official labeling advises that patients with high blood pressure should be closely monitored while on this treatment. Some official documents note that the co-administration with certain blood pressure medications, such as beta-blockers, may require the dose of one or both agents to be adjusted.


Q: Can Artan cause dizziness or lightheadedness?

Yes, regulatory documents list dizziness as a commonly reported adverse reaction. This reaction is one that can occur based on official labeling.


Q: What is the difference between the generic and brand versions of Artan?

The active ingredient (Trihexyphenidyl Hydrochloride) is chemically the same in both the generic and brand versions. The difference primarily relates to inactive ingredients (fillers and binders) used in the formulation and its specific market status.


Q: What is the mechanism of action of Artan, as described in the official literature?

Artan's mechanism of action is described as functioning as a muscarinic acetylcholine receptor antagonist. This means it blocks the activity of the natural chemical acetylcholine within the central nervous system to help restore the neurochemical balance that affects motor control.


Q: Is Artan safe to take if I have liver problems?

Regulatory documents describe that patients with liver disorders are considered to need close monitoring during treatment with this medication. This monitoring helps evaluate how the body is processing the drug.


Q: Is Artan available over the counter, or is it prescription-only?

The medicine is officially classified as a prescription-only medication. It is dispensed only with a valid prescription.


Q: Are there any known interactions between Artan and common supplements?

While specific interactions are not always detailed, regulatory documentation strongly advises patients to report all vitamins, minerals, herbal products, and other supplements to their healthcare provider. This is to ensure a full assessment of potential co-administration effects.


Q: Why do people in online forums talk about Artan causing fatigue?

The official product label lists drowsiness and weakness among the reported side effects. These effects may be perceived by some users as a feeling of fatigue.


Q: Is it normal to feel a change in appetite after starting Artan?

Yes, loss of appetite (anorexia) is listed as a potential adverse reaction reported with Artan in official documentation.


Q: How is Artan different from other drugs that treat the same condition?

Official documents describe Artan’s mechanism as directly blocking acetylcholine activity in the brain. This is a key difference from many other antiparkinson therapies that primarily work by modulating the dopamine system.


Q: What patient monitoring (like blood tests) is sometimes needed when using Artan?

Monitoring of intraocular pressure (eye pressure) is specifically advised for patients taking this medication. This monitoring is required to check for potential changes during treatment.


Q: Is it true that Artan can cause mood changes?

Official adverse reaction reports include psychiatric effects such as confusion, agitation, nervousness, and euphoria, which are changes in mental state or mood.


Q: Is Artan associated with any specific warnings regarding kidney function?

Regulatory documents indicate that patients with kidney disorders are described as needing close monitoring during treatment with Artan.


Q: Can Artan interact with non-prescription pain relievers?

Regulatory documentation advises patients to report all prescription and over-the-counter (OTC) medicines, including non-prescription pain relievers, to their healthcare provider for a safety check.


Q: What kind of evidence is there about stopping Artan?

Evidence summarized in official regulatory documents indicates that abrupt withdrawal of treatment may result in an acute worsening of Parkinsonism symptoms.


Q: Is it true that Artan can make other medications less effective?

Official documentation describes that Artan may be antagonistic to the actions of certain gastrointestinal motility agents. It may also reduce the absorption of co-administered Levodopa, which can affect that medication's activity.


Q: Does Artan contain gluten, lactose, or other common allergens?

The official labeling for the tablet dosage form lists magnesium stearate, microcrystalline cellulose, and sodium starch glycolate as inactive ingredients. While official labeling details the components, patients with allergies should note that the full excipient list is necessary for certainty.


Q: Do I need to avoid sun exposure while taking Artan?

Regulatory documents include a heat stroke warning and advise that the medication should be used with caution during hot weather due to the risk of reduced sweating (anhidrosis) and hyperthermia.


Q: Can children or teenagers use Artan?

Use in the pediatric population is not recommended according to regulatory documentation, as safety and effectiveness have not been established in this age group.


Q: Is Artan a controlled substance?

No, Artan is not classified as a controlled substance under federal drug schedules.


Q: What is the official description of Artan's storage conditions?

Official conditions describe storing the medication at controlled room temperature (20 C to 25 C). It should be kept in a tightly closed container and protected from excess heat and moisture.


Q: What are the most important things to mention to a healthcare provider before starting Artan?

Regulatory documents indicate that key pre-treatment discussions should include any history of glaucoma, existing heart/liver/kidney disorders, and the use of all other medicines or supplements.


Q: Does Artan affect sleep patterns?

Side effects reported in regulatory documents include both drowsiness and trouble sleeping (insomnia), which indicate a potential effect on sleep patterns.


Q: Is Artan metabolized by the liver?

Official regulatory text advises that patients with liver disorders require close monitoring. This is an indirect indication that liver function is relevant to the drug's processing or effect in the body.

How should Artan be stored and disposed of?

How to Store and Dispose of Artane (Trihexyphenidyl Hydrochloride)

The storage and disposal of Artane must strictly adhere to the conditions outlined in the official regulatory labeling to maintain stability and ensure safety.

Storage Requirement Official Condition
Temperature Range Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection Do not freeze. Protect from excess heat and moisture.
Container Rule Keep in the original, tightly closed container to protect the integrity of the product.
Child Safety Store the medication out of the sight and reach of children, securing it with locked safety caps.

Disposal of Artane that is outdated or no longer needed must follow established procedures. Unused product should be discarded according to the specific instructions provided by a healthcare professional or local waste disposal regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Artan found in:

A-Z Index: